EAPCI Column

DOI:

EAPCI Focus on the EAPCI Scientific Documents and Initiatives Committee

An interview with the Chair Giulio Stefanini

Figure 1

Figure 1.

What is the role of the committee?

Any proposal for scientific documents received by the EAPCI must be submitted to the Scientific Documents and Initiatives Committee (SDIC) for approval prior to their development. Together with my Co-Chair Nieves Gonzalo and committee members, the SDIC reviews all document proposals and makes approval or rejection recommendations. These recommendations are then reviewed and confirmed by the EAPCI Executive Committee. The responsibilities of the committee include the screening and validation of solicited and unsolicited documentation proposals as well as the identification of topics suitable for EAPCI scientific documents. Once the topic has been selected and approved, the committee is responsible for the administrative supervision and coordination of Writing Groups, coordination of the declarations of interest process for appointed authors as well as coordination of the review process.

How do EAPCI scientific documents benefit the community?

The key benefit of EAPCI scientific documents is to provide guidance for clinical management on topics not covered, or not covered in sufficient detail, in the existing or upcoming ESC Clinical Practice Guidelines. Whilst their topics and scope should not overlap with those of guidelines, scientific documents may complement them by providing more in-depth information in specific areas that cannot be expanded upon in guidelines. Our scientific documents evaluate scientific evidence, explore expert consensus in a structured way and, typically, include very practical advice for daily management of the topics discussed.

How are topics chosen and how can EAPCI members contribute?

Any EAPCI member may submit a proposal for a scientific document; any proposal received is subject to the robust and transparent review process of the SDIC followed by the EAPCI Executive Committee. Furthermore, one of the roles of the SDIC is to identify areas of unmet need and propose these topics to the EAPCI Executive Committee for consideration.

What are the upcoming topics?

  • Percutaneous coronary intervention in patients with cancer
  • Follow-up strategies in patients after transcatheter aortic valve replacement
  • Day-clinic care for percutaneous cardiovascular interventions
  • Sex-related considerations in mitral and tricuspid valve interventions

News

  • Attending ESC Congress 2023 in Amsterdam from August 25th-28th? Come to the ESC Plaza and find out more about EAPCI.
  • Not yet an EAPCI member? Join online https://www.escardio.org/EAPCI
Volume 19 Number 5
Aug 7, 2023
Volume 19 Number 5
View full issue

Suggested by Cory

Research Correspondence

10.4244/EIJ-D-25-00068 Jul 21, 2025
Intracoronary nicardipine to induce hyperaemia
Viscusi M et al

Editorial

10.4244/EIJ-E-25-00023 Jul 21, 2025
DAPT de-escalation post-ACS: a new rule or just a new option? Lessons from the 4D-ACS trial
Cuisset T and Cayla G
free

Viewpoint

10.4244/EIJ-D-24-00943 Jul 21, 2025
Factor XI inhibition for ACS patients: premises and prospects
Lopes R and Fanaroff A
free

State-of-the-Art

10.4244/EIJ-D-24-00387 Jul 21, 2025
Advances in coronary imaging of atherosclerotic plaques
Garcia-Garcia H et al
free

Research Correspondence

10.4244/EIJ-D-25-00025 Jul 21, 2025
Validation of the pullback pressure gradient in resting conditions
Sakai K et al

Editorial

10.4244/EIJ-E-25-00031 Jul 21, 2025
Supersaturated oxygen therapy to reduce myocardial infarct size: time to pay attention!
Stone G and Akinmolayemi O
free
Trending articles
224

State-of-the-Art Review

10.4244/EIJ-D-21-00426 Dec 3, 2021
Myocardial infarction with non-obstructive coronary artery disease
Lindahl B et al
free
172.65

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
80.3

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
47.75

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
47.75

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
23.7

Expert review

10.4244/EIJ-D-18-01180 Feb 20, 2020
Technical aspects in coronary sinus Reducer implantation
Giannini F et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved